Characterization of a protective monoclonal antibody recognizing Staphylococcus aureus MSCRAMM protein clumping factor A. - Wikidata - wikimedia - TriplyDB

Characterization of a protective monoclonal antibody recognizing Staphylococcus aureus MSCRAMM protein clumping factor A.

Characterization of a protective monoclonal antibody recognizing Staphylococcus aureus MSCRAMM protein clumping factor A.

http://www.wikidata.org/entity/Q34944592

about

Investigational drugs to treat methicillin-resistant Staphylococcus aureus Will there ever be a universal Staphylococcus aureus vaccine?A Structural Model of the Staphylococcus aureus ClfA–Fibrinogen Interaction Opens New Avenues for the Design of Anti-Staphylococcal Therapeutics Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey A recombinant clumping factor A-containing vaccine induces functional antibodies to Staphylococcus aureus that are not observed after natural exposure Identification of antigenic components of Staphylococcus epidermidis expressed during human infection.Subinhibitory concentrations of thymol reduce enterotoxins A and B and alpha-hemolysin production in Staphylococcus aureus isolates.Molecular characterization of the interaction of staphylococcal microbial surface components recognizing adhesive matrix molecules (MSCRAMM) ClfA and Fbl with fibrinogen.Comparison of antibody repertoires against Staphylococcus aureus in healthy individuals and in acutely infected patients.Role of Staphylococcus aureus global regulators sae and sigmaB in virulence gene expression during device-related infection.Characterization of a humanized monoclonal antibody recognizing clumping factor A expressed by Staphylococcus aureus.Comparative opsonic and protective activities of Staphylococcus aureus conjugate vaccines containing native or deacetylated Staphylococcal Poly-N-acetyl-beta-(1-6)-glucosamine.Preventing Staphylococcus aureus sepsis through the inhibition of its agglutination in blood.Opsonic and protective properties of antibodies raised to conjugate vaccines targeting six Staphylococcus aureus antigens.Functional antibodies targeting IsaA of Staphylococcus aureus augment host immune response and open new perspectives for antibacterial therapy.A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia In silico analysis for identifying potential vaccine candidates against Staphylococcus aureus.Phytol-based novel adjuvants in vaccine formulation: 2. Assessment of efficacy in the induction of protective immune responses to lethal bacterial infections in mice.Identification of anti-alpha toxin monoclonal antibodies that reduce the severity of Staphylococcus aureus dermonecrosis and exhibit a correlation between affinity and potency.Monoclonal Antibody Targeting Staphylococcus aureus Surface Protein A (SasA) Protect Against Staphylococcus aureus Sepsis and Peritonitis in Mice.The Staphylococcus aureus "superbug"Synthesis and evaluation of a conjugate vaccine composed of Staphylococcus aureus poly-N-acetyl-glucosamine and clumping factor A.Prevention of Staphylococcus aureus infections: advances in vaccine development.Exploring Staphylococcus aureus pathways to disease for vaccine development.Protective efficacy of the chimeric Staphylococcus aureus vaccine candidate IC in sepsis and pneumonia models Treatment options for multidrug-resistant bacteria.Antibody-Based Biologics and Their Promise to Combat Staphylococcus aureus Infections.Genetic elimination of the binding motif on fibrinogen for the S. aureus virulence factor ClfA improves host survival in septicemia.Staphylococcus aureus Clumping Factor A Remains a Viable Vaccine Target for Prevention of S. aureus Infection.Antibodies to capsular polysaccharide and clumping factor A prevent mastitis and the emergence of unencapsulated and small-colony variants of Staphylococcus aureus in mice.Successful selection of an infection-protective anti-Staphylococcus aureus monoclonal antibody and its protective activity in murine infection models SdrX, a serine-aspartate repeat protein expressed by Staphylococcus capitis with collagen VI binding activity.Lessons from the Crystal Structure of the S. aureus Surface Protein Clumping Factor A in Complex With Tefibazumab, an Inhibiting Monoclonal Antibody.Structural and functional role of Staphylococcus aureus surface components recognizing adhesive matrix molecules of the host.Multimechanistic Monoclonal Antibodies (MAbs) Targeting Staphylococcus aureus Alpha-Toxin and Clumping Factor A: Activity and Efficacy Comparisons of a MAb Combination and an Engineered Bispecific Antibody Approach.Staphylococcus aureus Aggregation and Coagulation Mechanisms, and Their Function in Host-Pathogen Interactions.Vaccines for Staphylococcus aureus and Target Populations.Two Dimensional Structural Analysis and Expression of a New Staphylococcus aureus Adhesin Based Fusion Protein Antibodies to Staphylococcus aureus capsular polysaccharides 5 and 8 perform similarly in vitro but are functionally distinct in vivo.

P2860

Q26780246-F9E50005-7FCF-4EB1-AD8C-963554E597A1 Q26824837-A3424774-CF3D-4595-BAEC-A156028BD931 Q27653017-00841170-0401-497A-A5BD-6E5E7C3AA545 Q28235095-58D221C2-B6CB-4BBD-B641-E97E5B2CDA72 Q28714292-F5C97551-8462-4748-9767-CF43C955E72D Q33251441-7392CD9D-CA51-4694-AA64-C32095D82CF0 Q33543783-4208268E-1507-4006-BEB9-2204EBF96454 Q33673559-48450192-E2F9-47F8-A10E-2EE4E88BE38A Q33716613-1C421B39-CAA5-43A0-B1CF-49814CFFCFF9 Q33788081-F333B015-76E6-4009-9166-31A6CEB4C0E9 Q33946739-6F107C42-7452-4BF7-AE41-4FBCA32FDA20 Q34033168-03380908-95DD-49BC-88C9-3B7732243F92 Q34058113-78EE4E65-F501-4455-A01A-E0C82F6DC395 Q34450382-16FB6DE6-2F01-4F62-BC0C-B23BBD6774E7 Q34483544-0E5B9B7E-624B-4131-8355-BCA7C238E12A Q34492730-FC6A0366-0740-4B2C-A00A-1956BCB2E2CC Q34973729-C0986CC2-7BB8-401B-B992-851487826AAF Q35035639-FE2D68F5-1A16-4208-9BA3-237564EE3466 Q35125351-15AC187E-AD96-449B-A91D-CCBD63CDE2EA Q35805321-4E17BDB7-8F4F-4FF2-BB4C-8B4FF6E9966A Q35939497-5E494F66-80DF-48F3-A5B3-B406911BEF75 Q35984316-FB4E3707-BDF0-45E8-AB19-BE1E20A1CBC6 Q36213353-ABD6A100-A72D-40C9-A834-A49CBECC2449 Q36284548-89E510D2-9E96-4FB3-98C1-2172985A5096 Q36516970-13E20B8A-BEA4-467C-A0D6-90B2ADE5E1C7 Q36569841-ABC93015-3550-4855-BA26-77CEB9CC5680 Q36607401-59432951-70E9-48BB-819E-910FE9AC936B Q36609408-C85BA81B-21F6-476B-A798-2AF82ACB0FE5 Q36666780-7A0FBA3F-8B2F-4613-97EE-A0164C09FE24 Q36736262-575EE0FA-B7F1-4C6F-81EA-8B2E20B133FE Q36974423-085524D9-946E-4DF2-B9B5-77DAAB8B9A9B Q37269558-3C5D25A0-5CCB-416F-B28C-0BB5DC1D1263 Q37582871-05D966D5-BE59-46F5-A2B8-32655624022A Q37605209-E7144BC0-3C78-48CE-844B-2E67F33C4977 Q37648719-92A84E75-64BD-45BE-BE85-159683550E23 Q38674449-30807296-A2B9-48C1-A47D-02B7557970C3 Q38938178-77F5AA5A-9403-45A3-90F0-3909A09A26E8 Q38961271-37C88A1A-3BDD-477F-A898-3F9CD55D83A5 Q39181004-A7A5FD73-6C16-46E1-A561-8976C30B233B Q40416064-4BF88ADD-CFC1-4E1F-BEDD-DCABA4D7639E

P2860

Characterization of a protective monoclonal antibody recognizing Staphylococcus aureus MSCRAMM protein clumping factor A.

http://www.wikidata.org/entity/Q34944592

description

2003 nî lūn-bûn

@nan

2003 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Characterization of a protecti ...... AMM protein clumping factor A.

@ast

Characterization of a protecti ...... AMM protein clumping factor A.

@en

Characterization of a protecti ...... AMM protein clumping factor A.

@nl

type

label

Characterization of a protecti ...... AMM protein clumping factor A.

@ast

Characterization of a protecti ...... AMM protein clumping factor A.

@en

Characterization of a protecti ...... AMM protein clumping factor A.

@nl

prefLabel

Characterization of a protecti ...... AMM protein clumping factor A.

@ast

Characterization of a protecti ...... AMM protein clumping factor A.

@en

Characterization of a protecti ...... AMM protein clumping factor A.

@nl

P1433

Q34944592-482C4C9A-DC9E-4BDF-837C-85BD51E7F1B5

P1476

Q34944592-2A6D31AD-D36D-4D45-930C-6DE072E74E8C

P2093

Q34944592-0B576CD0-B103-4177-834C-F6CC289E9FE7

Q34944592-36648781-F3C1-4F08-9AFC-1E865A7A6437

Q34944592-44810F77-728C-4A5C-BA1F-9EEF91C5F90C

Q34944592-643BBACF-A70D-4BD1-9B4F-131A032E368F

Q34944592-72742A57-B473-420E-9A01-75CD25843FA6

Q34944592-850C14FE-EEA1-4D8F-8143-20B68DBA7B43

Q34944592-936703CF-C9BC-4BB1-8316-B42C2E849842

Q34944592-9782ED99-F3CC-4450-B75B-3EE0FEA8C102

Q34944592-DFD5F1FC-3C40-47D3-AA75-CC9C3B3708B9

Q34944592-EC411D66-AF24-4A3D-9D75-0F6574817ABE

P2860

Q34944592-044850C4-E328-4D8D-9A2E-C31F8BF6DCB4

Q34944592-0653B5E0-5468-4732-BF9C-4BC61B24903A

Q34944592-071C1668-D3BA-4E06-B289-3706D532E35D

Q34944592-0767FF2B-9E44-4501-8C1E-CEC40E45F36D

Q34944592-0F141CF0-17A4-433C-9DB0-02619D31598B

Q34944592-13B1DB8D-583C-4DD6-A92C-20402E853567

Q34944592-18929334-43E6-42D0-80B3-5FAEBDF9372F

Q34944592-19A0936A-67EB-442F-AA65-7BD7C1261B64

Q34944592-1A70A02A-7280-41A2-87E5-38452F569341

Q34944592-1C8DE9E9-3C7D-4820-ABE5-1F9C30D70B21

P304

Q34944592-33920CF9-63D1-45A6-B435-C85F63C40976

P31

Q34944592-AFEA14AB-FC50-4A70-9E61-6C6B50E96632

P356

Q34944592-C9F09225-C125-48EB-A8C6-9108E59E50C7

P407

Q34944592-E35415CF-4853-466B-9F21-EDC51F0CC778

P433

Q34944592-2E75447D-3F0B-4875-96F3-34042F6D1F27

P478

Q34944592-41D110ED-DE20-4257-BB89-7D33F180AA60

P577

Q34944592-4100FED1-98CE-493D-B6B8-A0FB79E7EBB2

P698

Q34944592-E2CD37F3-C36E-4C94-9447-51A074197BD1

P921

Q34944592-022EEF03-4DB5-4228-8FB6-E6072163B348

P932

Q34944592-E09DC2D5-8331-4444-89CA-FCA625406ED3

P356

IAI.71.12.6864-6870.2003

P1433

Infection and Immunity

P1476

Characterization of a protecti ...... AMM protein clumping factor A.

@en

P2093

Andrea E Hall

http://www.w3.org/2001/XMLSchema#string

Elena L Gorovits

http://www.w3.org/2001/XMLSchema#string

Jeff T Hutchins

http://www.w3.org/2001/XMLSchema#string

John H Vernachio

http://www.w3.org/2001/XMLSchema#string

Joseph M Patti

http://www.w3.org/2001/XMLSchema#string

Julia M Ross

http://www.w3.org/2001/XMLSchema#string

Michael A Johnson

http://www.w3.org/2001/XMLSchema#string

Paul J Domanski

http://www.w3.org/2001/XMLSchema#string

Peter J Syribeys

http://www.w3.org/2001/XMLSchema#string

Pratiksha R Patel

http://www.w3.org/2001/XMLSchema#string

P2860

Passive immunity in prevention and treatment of infectious diseases

Shear stress affects the kinetics of Staphylococcus aureus adhesion to collagen.

Surface protein adhesins of Staphylococcus aureus.

Inhibition of Staphylococcus aureus adherence to collagen under dynamic conditions.

Expression of Staphylococcus aureus clumping factor A in Lactococcus lactis subsp. cremoris using a new shuttle vector

Clonal associations among Staphylococcus aureus isolates from various sites of infection

Study of Staphylococcus aureus pathogenic genes by transfer and expression in the less virulent organism Streptococcus gordonii

Clumping factor A mediates binding of Staphylococcus aureus to human platelets.

Antiviral therapy to prevent and treat hepatitis B virus infection in hepatic allografts.

Antibodies for the prevention and treatment of viral diseases.

P304

6864-6870

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/IAI.71.12.6864-6870.2003

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

71

http://www.w3.org/2001/XMLSchema#string

P577

2003-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

14638774

http://www.w3.org/2001/XMLSchema#string

P921

P932

308922

http://www.w3.org/2001/XMLSchema#string